StockData
MAZENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Maze Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$29.70+2.17 (+7.88%)

Close on Oct 19, 2026

Market cap
$1.75B
P/E (TTM)
–
Dividend yield
–

SEC filings

24 of Maze Therapeutics's most recent filings on SEC EDGAR

DocumentFormPeriodFiledSource
Current report8-KOct 15, 2026Oct 16, 2026SEC EDGAR
Current report8-KAug 13, 2026Aug 17, 2026SEC EDGAR
Quarterly report10-QJun 30, 2026Aug 11, 2026SEC EDGAR
Current report8-KAug 11, 2026Aug 11, 2026SEC EDGAR
Current report8-KJun 8, 2026Jun 10, 2026SEC EDGAR
Current report8-KMay 18, 2026May 22, 2026SEC EDGAR
Quarterly report10-QMar 31, 2026May 12, 2026SEC EDGAR
Current report8-KMay 12, 2026May 12, 2026SEC EDGAR
Proxy statementDEF 14AJun 8, 2026Apr 28, 2026SEC EDGAR
Current report8-KApr 21, 2026Apr 22, 2026SEC EDGAR
Annual report10-KDec 31, 2025Mar 25, 2026SEC EDGAR
Current report8-KMar 24, 2026Mar 25, 2026SEC EDGAR
Current report8-KFeb 2, 2026Feb 4, 2026SEC EDGAR
Quarterly report10-QSep 30, 2025Nov 6, 2025SEC EDGAR
Current report8-KNov 6, 2025Nov 6, 2025SEC EDGAR
Current report8-KOct 6, 2025Oct 6, 2025SEC EDGAR
Current report8-KSep 10, 2025Sep 11, 2025SEC EDGAR
Current report8-KSep 2, 2025Sep 2, 2025SEC EDGAR
Quarterly report10-QJun 30, 2025Aug 12, 2025SEC EDGAR
Current report8-KAug 12, 2025Aug 12, 2025SEC EDGAR
Quarterly report10-QMar 31, 2025May 14, 2025SEC EDGAR
Current report8-KMay 14, 2025May 14, 2025SEC EDGAR
Annual report10-KDec 31, 2024Mar 31, 2025SEC EDGAR
Current report8-KMar 31, 2025Mar 31, 2025SEC EDGAR